retatrutide phase 2 nejm 2023 obesity trial jastreboff 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Among participants 4 to 66
Description
Stentz FB, Lawson D, Tucker S, Christman J, Sands C
Market Players: The rise of new models like virtual-first care and organizations like Hims/Hers offering access to weight management programsincluding compounded or prescription GLP-1sfurther drives awareness and accessibility, increasing demand for employer coverage
Research also links GLP-1 medications to an increased risk of developing some health conditions
it is present in protein-rich meals [203]
Generally referred to as GLP-1 receptor agonists, the once a week injections can reduce appetite and food consumption, which in turn can reduce nutrient intake
doi: 10.2337/db10-1643 136 MaddurMSMiossecPKaveriSVBayryJ
